Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus

The Lancet Infectious Diseases

Volumn 17, Issue 6, 2017, Pages 645-653

  Glynn, Judith R ^a   Bower, Hilary ^a   Johnson, Sembia ^b   Houlihan, Catherine F ^c   Montesano, Carla ^d,e,f   Scott, Janet T ^h   Semple, Malcolm G ^h   Bangura, Mohammed S ^b   Kamara, Alie Joshua ^b   Kamara, Osman ^b   Mansaray, Saidu H ^b   Sesay, Daniel ^b   Turay, Cecilia ^b   Dicks, Steven ^g   Wadoum, Raoul E Guetiya ^d,e,f   Colizzi, Vittorio ^d,e,f   Checchi, Francesco ^b   Samuel, Dhan ^g   Tedder, Richard S ^g  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b SAVE THE CHILDREN   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e Sylvanus Koroma Campus   (Sierra Leone)

^f Holy Spirit Hospital   (Sierra Leone)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; GLYCOPROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ASYMPTOMATIC INFECTION; BLEEDING; BODY FLUID; CADAVER; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIARRHEA; DISEASE ASSOCIATION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOUSEHOLD; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL BIOPSY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; SIERRA LEONE; VOMITING; ASYMPTOMATIC INFECTIONS; BLOOD; FAMILY SIZE; HEMORRHAGIC FEVER, EBOLA; INFANT; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOGENICITY; PREVALENCE; PROCEDURES; SEROEPIDEMIOLOGY; SURVIVOR; VALIDATION STUDY; VIROLOGY;

ADOLESCENT; ADULT; AGED; ASYMPTOMATIC INFECTIONS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAMILY CHARACTERISTICS; FEMALE; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; SIERRA LEONE; SURVIVORS;

EID: 85014004093     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30111-1     Document Type: Article

References (29)

1. Bellan, SE, Pulliam, JRC, Dushoff, J, Meyers, LA, Ebola control: effect of asymptomatic infection and acquired immunity. Lancet 384 (2014), 1499–1500.
2. Blackley, DJ, Wiley, MR, Ladner, JT, et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains. Sci Adv, 2, 2016, e1600378.
3. Clark, DV, Kibuuka, H, Millard, M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 15 (2015), 905–912.
4. Leroy, EM, Baize, S, Volchkov, VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355 (2000), 2210–2215.
5. Ksiazek, TG, West, CP, Rollin, PE, Jahrling, PB, Peters, CJ, ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 179:suppl 1 (1999), S192–S198.
6. Pattyn, SR, (eds.) Ebola virus haemorrhagic fever, 1977, Elsevier/North-Holland Biomedical Press, Amsterdam.
7. Becker, S, Feldmann, H, Will, C, Slenczka, W, Evidence for occurrence of filovirus antibodies in humans and imported monkeys—do subclinical filovirus infections occur worldwide. Med Microbiol Immunol 181 (1992), 43–55.
8. Bausch, DG, Sequelae after Ebola virus disease: even when it's over it's not over. Lancet Infect Dis 15 (2015), 865–866.
9. Dowell, SF, Ebola hemorrhagic fever: why were children spared?. Pediatr Infect Dis J 15 (1996), 189–191.
10. Glynn, JR, Age-specific incidence of Ebola virus disease. Lancet, 386, 2015, 432.
11. Helleringer, S, Noymer, A, Clark, SJ, McCormick, T, Did Ebola relatively spare children?. Lancet 386 (2015), 1442–1443.
12. Bower, H, Johnson, S, Bangura, MS, et al. Exposure-specific and age-specific attack rates for Ebola virus disease in Ebola-affected households, Sierra Leone. Emerg Infect Dis 22 (2016), 1403–1412.
13. Lambe, T, Rampling, T, Samuel, D, et al. Detection of vaccine induced antibodies to Ebola virus in oral fluid. Open Forum Infect Dis, 3, 2016, ofw031.
14. WHO, Sierra Leone Ministry of Health. Clinical management of patients in the Ebola treatment centres and other care centres in Sierra Leone. Interim emergency guidelines. http://nerc.sl/?q=sierra-leone-ebola-treatment-centre-pocket-guide-15-dec-2014, 2014 (Dec 5, 2016).
15. Bower, H, Smout, E, Bangura, MS, et al. Deaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort study. BMJ, 353, 2016, i2403.
16. WHO/International Study Team. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56 (1978), 271–293.
17. Rowe, AK, Bertolli, J, Khan, AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179:suppl 1 (1999), S28–S35.
18. Bertherat, E, Renaut, A, Nabias, R, Dubreuil, G, Georges-Courbot, MC, Leptospirosis and Ebola virus infection in five gold-panning villages in northeastern Gabon. Am J Trop Med Hyg 60 (1999), 610–615.
19. Richardson, ET, Kelly, JD, Barrie, MB, et al. Minimally symptomatic infection in an Ebola ‘hotspot’; a cross-sectional serosurvey. PLoS Negl Trop Dis, 10, 2016, e0005087.
20. Fallah, M, Prevail III Research Team. A cohort study of survivors of Ebola virus infection in Liberia (PREVAIL III). Conference on Retroviruses and Opportunistic Infections; Boston, USA; Feb 22–25, 2016. http://www.croiwebcasts.org/console/player/29569?mediaType=slideVideo& (accessed Dec 5, 2016).
21. Leroy, EM, Baize, S, Debre, P, Lansoud-Soukate, J, Mavoungou, E, Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 124 (2001), 453–460.
22. McElroy, AK, Erickson, BR, Flietstra, TD, et al. Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis 20 (2014), 1683–1690.
23. Deen, GF, Knust, B, Broutet, N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1511410 published online Oct 14.
24. WHO. Interim guidance. Clinical care for survivors of Ebola virus disease WHO/EVD/OHE/PED/16.1 Rev.2. http://apps.who.int/iris/bitstream/10665/204235/1/WHO_EVD_OHE_PED_16.1_eng.pdf, 2016 (accessed Dec 5, 2016).
25. Ksiazek, TG, Rollin, PE, Williams, AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179:suppl 1 (1999), S177–S187.
26. Sobarzo, A, Groseth, A, Dolnik, O, et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 208 (2013), 299–309.
27. Dowell, SF, Mukunu, R, Ksiazek, TG, Khan, AS, Rollin, PE, Peters, CJ, Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179:suppl 1 (1999), S87–S91.
28. Brainard, J, Hooper, L, Pond, K, Edmunds, K, Hunter, PR, Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis. Int J Epidemiol 45 (2016), 102–116.
29. Lindblade, KA, Nyenswah, T, Keita, S, et al. Secondary Infections with Ebola virus in rural communities, Liberia and Guinea, 2014–2015. Emerg Infect Dis 22 (2016), 1653–1655.